Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Fig. 4

KLF4 represses transcription of the EGFR gene. a RT-qPCR quantitation of EGFR mRNA levels following infection of MDA-MB-231 (231) and MDA-MB-468 (468) cells with AdGFP or AdKLF4. b RT-qPCR analysis of EGFR mRNA after silencing KLF4 in MCF10A cells. c Schematic of EGFR promoter-specific sites (1–6) used to detect KLF4 binding by ChIP-PCR. Three primer sets (A/B, C/D, and E/F) were used as indicated in the schematic and labels. Primers are listed in Table S1. d Gene-specific ChIP-PCR gel of MCF10A cells assessing the binding of KLF4 protein to the EGFR gene locus (hg19) where K1 and K2 are technical replicates for KLF4 immunoprecipitation. e Quantitation of d relative to the input. a, b Completed in three independent experiments in triplicate with *p < 0.05. d, e Completed in two independent experiments in duplicate

Back to article page